Home
About
 Us
Overview
Management
Ethics
Patents
Products
VASCADE
®
Safe
Simple
Guaranteed
Ordering Info
Videos
VASCADE
®
 MVP
Early Ambulation
Simple
Proven
Ordering Info
Videos
CATALYST
Overview
Easy to Use
Clinical Data
Ordering Info
Videos
NEWS: 
Wall Street Journal Pro – Raises $41 Million.
MORE
Value to Hospital
Patients
Resources
News
Press Releases
Announces Positive Results of the Pivotal Study Evaluating the System Compared to Manual Compression for Multi-Vessel Closure Following Electrophysiology Procedures
to Present New Clinical Data on the System for Multi-Vessel Closure Following Electrophysiology Procedures
Awarded Internationally Recognized Shingo Bronze Medallion From the Shingo Institute for Operational Excellence
Announces Completion of the Pivotal Trial
®
 Announces Approval of VASCADE
®
 Vascular Closure System for Use in Femoral Vein Closure
Brings Total Financing Round to $41 Million; Announces Sponsorship of Trial, First Vascular Closure Trial Targeted at High Growth Electrophysiology Procedures
®
 Raises $30 Million
Medical, Inc. Announces Appointment of Lisa Garrett, Chief Financial Officer and of Human Resources
Medical, Inc. Announces Appointment of John Russell, President and Chief Executive Officer
Medical, Inc. Completes Series 3 Private Equity Financing and Secures Debt Facility with Capital
Medical, Inc. Announces Appointment of Randy Hubbell, Chief Commercial Officer
Medical, Inc. Announces Approval for VASCADE™ Vascular Closure System
Medical, Inc. Announces That It Has Obtained Approval to Apply the European Mark to Its VASCADE™ Vascular Closure System (VCS)
Medical, Inc. Completes Third Tranche of Series 2 Private Equity Financing
Submits Final Module to for VASCADE™ Vascular Closure System
Medical, Inc. Announces Completion of Enrollment in the Clinical Trial Aimed at Demonstrating the Safety and Efficacy of the Vascular Closure System
Medical, Inc. Completes First Tranche of Series 2 Private Equity Financing
Medical, Inc. Announces Appointment of Charles Maroney, President and Chief Executive Officer
Announces Approval of the Vascular Closure System for Multi-Site Vessel Closure Following Electrophysiology Procedures
Contact Us
Careers
Ethics
Overview
Management
Ethics
Patents
Code of Business Conduct and Ethics
Medical, Inc.’s management and employees are dedicated to high ethical standards and recognize the Company’s duty to conduct its affairs within the bounds of the law. The Company has formalized certain business policies and practices in this Code of Business Conduct and Ethics. The Code of Conduct is designed to ensure that the Company and its employees and agents are in compliance with all applicable laws and regulations concerning good engineering, clinical, manufacturing, laboratory, regulatory, labeling, sales and marketing activities, third-party reimbursement of the cost of its products, human resources and environmental practices.
Company Milestones
VASCADE
®
 receives approval for 6-12Inner Diameter (ID) multi-vessel venous vascular closure
Antegrade Study results published in Vascular Disease Management in 2018
VASCADE
®
 receives approval for use in femoral veins in 2018
approved by the in 2013
approved for Mark in Europe in 2012
received 510(k) clearance in 2009
approved for Mark in Europe in 2008
received 510(k) clearance in 2007
About Us
Products
Value to Hospital
Patients
Resources
News
Contact Us
© 2018 Cardival Medical, Inc. VASCADE
®
 and CATALYST
®
  are registered trademarks of Medical, Inc.
Document Portal
Privacy Policy
Site Map